SPPAM
BBIO icon

Summit Partners Public Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Summit Partners Public Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.3M Buy
621,125
+268,294
+76% +$18.8M 0.81% 39
2026
Q1 		$26.2M Sell
352,831
-460,963
-57% -$33.4M 0.7% 49
2025
Q4 		$62.2M Buy
813,794
+7,084
+0.9% +$465K 1.29% 27
2025
Q3 		$41.9M Buy
806,710
+48,965
+6% +$2.39M 0.87% 44
2025
Q2 		$32.7M Sell
757,745
-371,847
-33% -$13.5M 0.83% 40
2025
Q1 		$39M Buy
+1,129,592
New +$38.1M 1% 35

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Summit Partners Public Asset Management's BBIO Position: Q2 2026 in Review

Summit Partners Public Asset Management increased its BridgeBio Pharma (BBIO) stake by 76% in Q2 2026, buying an estimated $18.8M and bringing the position to 621,125 shares worth $46.3M. The position accounts for 0.81% of the portfolio, ranked #39.

Summit Partners Public Asset Management first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $62.2M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Summit Partners Public Asset Management held 621,125 shares of BridgeBio Pharma worth $46.3M as of Q2 2026.
  • Summit Partners Public Asset Management bought 268,294 BridgeBio Pharma shares in Q2 2026, an estimated $18.8M.
  • BridgeBio Pharma made up 0.81% of Summit Partners Public Asset Management's portfolio in Q2 2026, its #39 holding.
  • Summit Partners Public Asset Management first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • Summit Partners Public Asset Management's BridgeBio Pharma position peaked at $62.2M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.